RETRACTED: CRISPR/Cas9-Mediated OC-2 Editing Inhibits the Tumor Growth and Angiogenesis of Ovarian Cancer

Lu, Tongyi; Zhang, Ligang; Zhu, Wenhui; Zhang, Yinmei; Zhang, Simin; Wu, Binhua; Deng, Ning

doi:10.3389/fonc.2020.01529

ORIGINAL RESEARCH article

Front. Oncol. , 02 September 2020

Sec. Cancer Molecular Targets and Therapeutics

Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.01529

RETRACTED: CRISPR/Cas9-Mediated OC-2 Editing Inhibits the Tumor Growth and Angiogenesis of Ovarian Cancer

Retracted

A retraction of this article was approved in:

Retraction: CRISPR/Cas9-Mediated OC-2 Editing Inhibits the Tumor Growth and Angiogenesis of Ovarian Cancer
1. Read retraction

$\r\nTongyi Lu&#x;$ Tongyi Lu^†

Ligang Zhang^†

Wenhui Zhu^†

Yinmei Zhang

Simin Zhang

Binhua Wu

Ning Deng^*

Guangdong Province Engineering Research Center for Antibody Drug and Immunoassay, Department of Biology, Jinan University, Guangzhou, China

This article has been retracted. Please follow the link to the full retraction notice for details.

Citation: Lu T, Zhang L, Zhu W, Zhang Y, Zhang S, Wu B and Deng N (2020) CRISPR/Cas9-Mediated OC-2 Editing Inhibits the Tumor Growth and Angiogenesis of Ovarian Cancer. Front. Oncol. 10:1529. doi: 10.3389/fonc.2020.01529

Received: 22 January 2020; Accepted: 16 July 2020;
Published: 02 September 2020; Retracted: 07 May 2021.

Edited by:

Christina Annunziata, National Cancer Institute (NCI), United States

Reviewed by:

Paolo Armando Gagliardi, University of Bern, Switzerland
Xudong Tang, Guangdong Medical University, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

RETRACTED: CRISPR/Cas9-Mediated OC-2 Editing Inhibits the Tumor Growth and Angiogenesis of Ovarian Cancer

95% of researchers rate our articles as excellent or good

95% of researchers rate our articles as excellent or good